Sobi publishes 2015 Annual Report
Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) today published its 2015 Annual Report, themed "A new chapter of our story". The integrated report summarises the business as well as financial highlights for 2015, and gives a deeper insight into the company's strategic agenda and its patient-centric innovation model.
The 2015 Annual Report is available both in print and as an interactive online version, in responsive design to enable viewing on all mobile devices. New features in the online version include pdf and excel downloads of the report and the financial results as well as video comments from CEO Geoffrey McDonough and stakeholders.
CEO and President Geoffrey McDonough wrote in his letter to the shareholders, "We believe that the culture of pioneering in the service of patients with rare diseases requires a small, agile, and human scale organisation that can stay responsive to the changing landscape of patient needs, science and society. We began our transition five years ago and over this period Sobi's market capitalisation has increased more than sevenfold."
To read the digital version of the report please follow this link.
To read or download the annual report in Swedish, please follow this link.
To read or download the annual report in English, please follow this link.
To order a printed copy, please send an email to firstname.lastname@example.org.
Sobi(TM) is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ Stockholm.
For more information please contact
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
Sobi announces the information set out in this press release pursuant to the Swedish Securities Market Act. The information was submitted for publication at 07.45 CET on 27 April 2016.